Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 6Lymphoma, Extranodal NK-T-Cell 6Carcinoma, Hepatocellular 5Stomach Neoplasms 3Nasopharyngeal Carcinoma 3Locally Advanced Rectal Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Melanoma 2Epstein-Barr Virus Infections 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Objective Response Rate 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, T-Cell 1Lymphoma 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 7Doxorubicin 5Vincristine 4fludarabine phosphate 3Gemcitabine 3Alemtuzumab 3Psychiatric Rehabilitation 2Prednisone 2Prednisolone 2Mycophenolic Acid 2Methylprednisolone 2Flow Cytometry 2Cyclosporine 2Cisplatin 2Antilymphocyte Serum 2spartalizumab 1sargramostim 1romidepsin 1prednylidene 1pirarubicin 1motesanib diphosphate 1etoposide phosphate 1Therapeutics 1Thalidomide 1Sensitivity and Specificity 1Rituximab 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Immunoblastic Lymphadenopathy × spartalizumab × Clear all
NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

The First Hospital of Jilin University

Phase NA Unknown
34 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡